[{"uuid": "8dc9c12d-7ce5-3c57-915b-8ffc0af67e97", "title": "Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/arvinas-report-fourth-quarter-full-120000526.html", "providerPublishTime": 1738584000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/THk8GpbFdRBalzjrkr1Fkw--~B/aD0yNTI7dz02OTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 696, "height": 252, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/OoRHVzB5LzSonS2J1PndgQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARVN"]}, {"uuid": "f0514a7c-23d6-36b3-949e-b4827e48c5c3", "title": "2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025", "publisher": "Motley Fool", "link": "https://finance.yahoo.com/m/f0514a7c-23d6-36b3-949e-b4827e48c5c3/2-growth-stocks-that-could.html", "providerPublishTime": 1737451740, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/AffShvwZ_vwPA_tF4I195w--~B/aD0xNDE0O3c9MjEyMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/7d030c71e5c78e8a4a99f01b548a3215", "width": 2121, "height": 1414, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Pbw7eq.MogDqpzr2VD7pUQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/7d030c71e5c78e8a4a99f01b548a3215", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["RXRX", "ARVN"]}, {"uuid": "52399048-243e-3fb7-9ded-edcb176eae91", "title": "Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/arvinas-shares-fall-amid-breast-193703417.html", "providerPublishTime": 1736537823, "type": "STORY", "relatedTickers": ["ARVN", "PFE"]}, {"uuid": "4092899b-0a6c-3b01-82b7-61a884dddc8a", "title": "Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/arvinas-updates-guidance-first-second-120000072.html", "providerPublishTime": 1736510400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/THk8GpbFdRBalzjrkr1Fkw--~B/aD0yNTI7dz02OTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 696, "height": 252, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/OoRHVzB5LzSonS2J1PndgQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARVN"]}, {"uuid": "1b687e5d-5c9c-3025-a322-0877f4c27c11", "title": "Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/arvinas-pfizer-present-apos-encouraging-150508274.html", "providerPublishTime": 1733843108, "type": "STORY", "relatedTickers": ["PFE", "ARVN"]}, {"uuid": "e62d355c-db8b-3e37-8a12-8bd7f2d6599e", "title": "Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-arvinas-inc-arvn-among-181917216.html", "providerPublishTime": 1733336357, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/j5uhrEZUavYRbCJ_QzdzwA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0e17a7fb4459fa588c7c35d998f2441a", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/bZSBVqN8x0JZakRDTTn1Zg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0e17a7fb4459fa588c7c35d998f2441a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARVN"]}, {"uuid": "e06710aa-b0c6-3454-8aee-87ca4b1482f9", "title": "Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/arvinas-pfizer-partner-cancer-drug-182307804.html", "providerPublishTime": 1733854987, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/8D1NdfuTjyt6Ht5ptJbWQg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/7f52ad0ab6f02f41c64fd7b2b1af5a02", "width": 1000, "height": 563, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/cSUxhzRT9YSZhrfDrOepGQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/7f52ad0ab6f02f41c64fd7b2b1af5a02", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARVN", "PFE"]}, {"uuid": "6fc981d6-2466-3c06-b2e9-0fd7a8723f94", "title": "Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/arvinas-inc-arvn-small-cap-140607903.html", "providerPublishTime": 1732025167, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/j5uhrEZUavYRbCJ_QzdzwA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0e17a7fb4459fa588c7c35d998f2441a", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/bZSBVqN8x0JZakRDTTn1Zg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0e17a7fb4459fa588c7c35d998f2441a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARVN", "^RUT"]}, {"uuid": "d90c0921-7ff2-3b5f-a080-287473edd63d", "title": "Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/arvinas-announces-upcoming-vepdegestrant-poster-223500934.html", "providerPublishTime": 1732574100, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/THk8GpbFdRBalzjrkr1Fkw--~B/aD0yNTI7dz02OTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 696, "height": 252, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/OoRHVzB5LzSonS2J1PndgQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARVN"]}, {"uuid": "f81ae1e2-55a7-3633-8f1e-22daa9702f8a", "title": "Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/arvinas-pfizer-announce-initial-phase-140500237.html", "providerPublishTime": 1733839500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/THk8GpbFdRBalzjrkr1Fkw--~B/aD0yNTI7dz02OTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 696, "height": 252, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/OoRHVzB5LzSonS2J1PndgQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["PFE", "ARVN"]}, {"uuid": "1b1116af-a2a9-38ba-ba25-fab8a8692c69", "title": "Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/arvinas-present-piper-sandler-36th-120000666.html", "providerPublishTime": 1732708800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/THk8GpbFdRBalzjrkr1Fkw--~B/aD0yNTI7dz02OTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 696, "height": 252, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/OoRHVzB5LzSonS2J1PndgQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARVN"]}, {"uuid": "4308a47c-3cec-3fd6-a596-10b5ba322734", "title": "Arvinas and Pfizer\u2019s combo therapy shows promise in breast cancer trial", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/4308a47c-3cec-3fd6-a596-10b5ba322734/arvinas-and-pfizer%E2%80%99s-combo.html", "providerPublishTime": 1733913505, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/S1Blsa2iR0KCQctm52vzqQ--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/bf01288e9800603cfd7b1729a35a7d8a", "width": 1440, "height": 810, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ISU9LXpLU_blr0M2DwNM1A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/bf01288e9800603cfd7b1729a35a7d8a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["PFE", "ARVN"]}]